Cargando…
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells
Combination treatment is a promising strategy to improve prognosis of hepatocellular carcinoma (HCC). Sorafenib is a traditional first-line agent approved for the treatment of advanced HCC, though with limited efficacy. Previously, we reported that lonafarnib, an orally bioavailable non-peptide inhi...
Autores principales: | Wang, Jialiang, Wei, Huan, Huang, Yanlin, Chen, Dongmei, Zeng, Guofen, Lian, Yifan, Huang, Yuehua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710066/ https://www.ncbi.nlm.nih.gov/pubmed/31409760 http://dx.doi.org/10.18632/aging.102165 |
Ejemplares similares
-
Correction for: The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2019) -
Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells
por: Wang, Jialiang, et al.
Publicado: (2017) -
Overexpressing CCT6A Contributes To Cancer Cell Growth By Affecting The G1-To-S Phase Transition And Predicts A Negative Prognosis In Hepatocellular Carcinoma
por: Zeng, Guofen, et al.
Publicado: (2019) -
Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021) -
Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma
por: Chen, Lubiao, et al.
Publicado: (2019)